Compare GF & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GF | SGMO |
|---|---|---|
| Founded | 1990 | 1995 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.9M | 155.1M |
| IPO Year | N/A | 2000 |
| Metric | GF | SGMO |
|---|---|---|
| Price | $11.92 | $0.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.60 |
| AVG Volume (30 Days) | 28.1K | ★ 4.0M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $32,875,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.38 | $0.38 |
| 52 Week High | $9.41 | $1.40 |
| Indicator | GF | SGMO |
|---|---|---|
| Relative Strength Index (RSI) | 65.78 | 47.44 |
| Support Level | $11.88 | $0.43 |
| Resistance Level | $12.49 | $0.48 |
| Average True Range (ATR) | 0.19 | 0.02 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 57.85 | 53.88 |
NEW GERMANY FUND INC is a non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.